Recon: Pfizer begins Phase 2/3 trial of oral drug for COVID prevention; Biohaven's multiple system atrophy candidate fails in Phase 3
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy